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 RENAL DYSFUNCTION, CARDIOVASCULAR RISK, AND THE RESPONSE 
TO ACE INHIBITION IN PATIENTS AFTER MYOCARDIAL INFARCTION. 
Powell Jose, Charles Tomson, Hicham Skali, Jean L. Rouleau, Harlan M. Krumholz, 
Marc A. Pfeffer, Scott D. Solomon for the SAVE Investigators. Cardiovascular Medicine 
Division, Brigham & Women’s Hospital, Boston MA. (Sponsored by Lawrence H. Young, 
Section of Cardiovascular Medicine, Yale University School of Medicine) 
 
Background: Proteinuria is a known cardiovascular risk factor in hypertensive or 
diabetic patients as well as the general population.  Worsening renal function (WRF) has 
been shown to influence outcomes in the heart failure population.  The prognostic value 
of these markers for renal dysfunction in patients after myocardial infarction is unclear. 
Methods: The Survival and Ventricular Enlargement trial (SAVE) randomized 2231 
patients with left ventricular dysfunction between 3-16 days (average 11 days) post-MI to 
receive captopril or placebo; those with a serum creatinine above 2.5mg/dl were excluded 
from SAVE.  WRF was defined as an increase in creatinine greater-than 0.3mg/dl 
measured from baseline to two weeks after randomization.  A subset of 583 SAVE 
patients who underwent baseline dipstick urinalysis was also studied.  We examined the 
predictive values of WRF and proteinuria on cardiovascular outcomes during 42 months 
of follow-up.  We then explored the potential interaction between these markers of renal 
dysfunction and the response to angiotensin-converting enzyme (ACE) inhibition.  
Results: Proteinuria was present in 20.9% of patients who were generally older, more 
often hypertensive, and who had lower ejection fractions and glomerular filtration rates.  
Proteinuria was associated with an increased risk of death (HR 1.84, 95%CI 1.20-2.82).  
In 1854 subjects with paired serum creatinine measurements, WRF occurred in 223 
subjects (12.0%) and had no significant association with ACE inhibitor therapy (p=0.38).  
WRF was a stronger predictor of death (HR 1.55, 95%CI 1.15-2.11) than baseline serum 
creatinine (HR 1.47, 95%CI 1.05-2.05).  The absolute benefit of captopril therapy was 
greatest for patients with proteinuria (p=0.02), but not for those with WRF (p=0.40). 
Conclusions: Proteinuria and WRF were not uncommon in patients after myocardial 
infarction, and were strongly associated with increased risk for death and cardiovascular 
outcomes irrespective of baseline renal function.  Patients randomized to captopril did not 
demonstrate more WRF than patients receiving placebo, and subjects with proteinuria 
who took captopril had the highest reduction in cardiovascular outcomes.   
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 INTRODUCTION 
 
 
Chronic kidney disease is an established cardiovascular risk factor.  Renal 
function is considered as powerful an adverse prognostic factor for mortality as clinical 
variables such as ejection fraction and New York Heart Association function class (1).  
Individuals with renal dysfunction are more likely to die from cardiovascular disease than 
renal failure.  Patients with end-stage renal disease are at a risk for cardiovascular 
outcomes that is 10-20 times greater than age and sex-matched controls in the general 
population (2).  The increase in risk is partly due to nontraditional cardiovascular risk 
factors that are present in renal disease, such as anemia, disrupted calcium-phosphate 
metabolism, and microalbuminuria.  In addition, the “cardiorenal syndrome” has been 
described as a pathophysiological condition in which combined cardiac and renal 
dysfunction accelerates the rate of cardiovascular morbidity and mortality due to distinct 
properties that do not occur in conditions affecting each organ independently (3).   
  Two markers of renal dysfunction, proteinuria and reduced glomerular filtration 
rate (GFR), are known clinical manifestations of kidney disease that have demonstrated 
separate associations to end-stage renal disease as well as cardiovascular morbidity and 
mortality.  Proteinuria and reduced GFR have each been proven to increase risk in 
patients with chronic diseases as well as the general population.  The Seventh Report of 
the Joint National Committee (JNC-7) has incorporated both albuminuria and decreased 
GFR into the group of major cardiovascular risk factors (4).     
Proteinuria is a known predictor of morbidity and mortality, and has consistently 
been shown to influence outcomes in patients even after adjustment for GFR and 
irrespective of other cardiovascular risk factors such as diabetes or hypertension (5-11).  
 
 Microalbuminuria, which is below the limit of detection of albumin excretion in standard 
urine dipsticks, is now considered a target for treatment in diabetics.  The Framingham 
Heart Study, Prevention of Renal and Vascular End-stage Disease Study (PREVEND), 
and other observational studies have suggested the utility of screening for 
microalbuminuria in the general population as a method of risk stratification for 
cardiovascular disease (12-14). 
Reduced GFR is a strong independent predictor of cardiovascular outcomes and 
mortality in the general population (15) following myocardial infarction (16-20) and 
heart failure (21, 22).  Worsening renal function (WRF), defined as small increases in 
creatinine over a specified period of time, has been assessed in heart failure patients as an 
independent prognostic marker (23, 24).  In patients hospitalized for acute heart failure, 
WRF was a stronger predictor of death than the initial level of creatinine (25).  WRF has 
been associated in these studies with in-hospital mortality, longer length of stay, higher 
rates of hospital readmission, and increased risk of death six months after discharge.  
Medical therapies that have been explored in treating heart failure patients with 
renal dysfunction include diuretics, inotropic agents, vasodilators, and natruetic peptides, 
but data have remained largely inconclusive.  Angiotensin converting enzyme (ACE) 
inhibitors have been shown to reduce cardiovascular morbidity and mortality in patients 
with heart failure or systolic dysfunction (26-28), following myocardial infarction (29-
33), and in patients at high risk for vascular events (34, 35).  Having also been proven as 
nephroprotective (36-38), the potential benefit of ACE inhibitors to both improve renal 
function and lower cardiovascular risk is an area that must be explored in more detail.  
Despite supportive evidence suggesting the renal benefits of ACE inhibition, cross-
 
 sectional analyses have documented that patients with lower GFR do poorly because they 
are less likely to receive medications such as ACE inhibitors, B-blockers, aspirin or 
revascularization procedures such as PTCA and CABG (39).  Fears of renal clearance, 
hypotension, or acute renal failure have led to a state of “therapeutic nihilism” in treating 
patients with renal dysfunction; this has also been suggested as an explanation for the 
increased cardiovascular risk seen in these patients (39).  Large prospective clinical trials 
using ACE inhibitors generally do not include patients with advanced renal dysfunction.  
ACE inhibition has proven efficacy in reducing microalbuminuria in diabetic and 
hypertensive patients (5, 40).  However, the impact of reducing proteinuria on 
cardiovascular outcomes, particularly in the post-MI population, is not yet clear. 
Furthermore, whether treatment of post-MI patients with ACE inhibitors is associated 
with WRF or affects outcomes in patients with WRF is unknown. 
  
 
STATEMENT OF PURPOSE 
 
 
The impact of proteinuria and WRF as risk factors for cardiovascular outcomes 
after acute myocardial infarction is not well characterized.  We analyzed patients enrolled 
in the Survival and Ventricular Enlargement (SAVE) Trial to determine the prognostic 
importance of proteinuria and worsening renal function on cardiovascular outcomes.  We 
also evaluated whether the response to ACE inhibition in reducing cardiovascular events 
is affected by the presence of these markers of renal dysfunction.   
Most of the literature involving the cardiorenal syndrome stems from analyses 
done in heart failure patients.  As patients are living longer with coronary artery disease 
 
 due to advancements in cardiac catheterization and surgery, the utilization of medical 
therapies, particularly ACE inhibition, in patients who develop the cardiorenal syndrome 
after myocardial infarction must be better understood.  In addition to summarizing the 
analyses performed in SAVE, this thesis also aims to provide a comprehensive overview 
of the cardiorenal syndrome as it pertains to patients after myocardial infarction or who 
have established coronary artery disease.  We conducted additional analyses using data 
from the Cholesterol and Recurrent Events (CARE) Study and the Prevention of Events 
with ACE Inhibition (PEACE) Trial to characterize the cardiovascular risk associated 
with having the combination of proteinuria and reduced GFR as well as the impact of 
ACE inhibition in lowering cardiovascular events for patients with reduced GFR.   
 
METHODS 
 
Subjects: 
The SAVE trial was a randomized, double-blind placebo-controlled trial 
examining the use of the ACE inhibitor captopril in 2231 patients with acute myocardial 
infarction and left ventricular dysfunction (ejection fraction ≤ 40%), but without overt 
heart failure (29).  Patients were randomized to receive captopril (50mg po tid) or 
placebo commencing between 3 and 16 days post-MI.  The trial excluded patients with a 
serum creatinine above 2.5mg/dl.  SAVE demonstrated that long-term administration of 
captopril to recent survivors of MI with left ventricular dysfunction resulted in improved 
survival and reduced morbidity and mortality.  The reduction in risk was significant for 
all-cause mortality (19%, 95% confidence interval [CI] 3-32%), cardiovascular death 
(21%, 95%CI 5-35%), development of severe heart failure (37%, 95%CI 20-50%), 
hospitalization for congestive heart failure (22%, 95%CI 4-37%), and recurrent 
 
 myocardial infarction (25%, 95%CI 5-40%).  The trial was conducted from 1988-1991 in 
Canada and the United States.  
 
Proteinuria 
 
All Canadian patients in SAVE were required to undergo dipstick urinalyses 
because of safety concerns during administration of study drug.  Baseline dipstick 
urinalyses were performed on average 10 days post-MI.  Typical dipstick classification of 
proteinuria included none, trace, 1+, 2+, 3+, 4+, corresponding to urinary protein 
concentrations of <10mg/dl, 10-30, 30-100, 100-300, and >1000mg/dl, respectively (41).  
The 4-variable Modification of Diet in Renal Disease equation: 
[186xserum creatinine -1.154 x age in years -0.203 x 1.210 (if black) x 0.742 (if female)] 
was used to estimate GFR, which has been shown to agree with iothalamate 
measurements of GFR (42).  From an initial 658 subjects enrolled in Canada, baseline 
dipstick measures were available in 598 patients; we excluded an additional 15 patients 
due to missing serum creatinine measurements, leaving 583 subjects for analysis.   
 
Worsening Renal Function 
 
All subjects received a captopril test dose of 6.25mg; patients who developed 
hypotensive symptoms or ischemia after initiation of study drug (n=23) were excluded 
from the trial.  Subjects were randomized to receive captopril or placebo commencing 
between 3 and 16 days post-MI.  The titration scheme involved an initial dose of 12.5mg 
which was advanced as tolerated up to 25mg TID prior to discharge.  During an 
outpatient visit approximately two weeks later at the discretion of site investigators the 
dose was to be doubled.  Serum creatinine was measured at baseline as well as during the 
 
 outpatient visit after two weeks.  From the initial 2231 subjects, there were 356 subjects 
missing serum creatinine measurements at either baseline (n=31) or two weeks (n=325), 
and 21 subjects who had a cardiovascular event occur prior to two weeks, leaving for 
analysis 1854 randomized and consenting SAVE subjects with baseline and two week 
serum creatinine measurements who at the first outpatient visit had no cardiovascular 
events.  When stratifying the risk of WRF by treatment, 41 additional subjects were not 
taking captopril due to dropout, leaving 1813 subjects with paired samples and no 
cardiovascular events who after two weeks were taking their assigned study medication.     
 
Statistical Analysis: 
Proteinuria 
We considered trace or higher protein on dipstick as evidence of proteinuria.  
Multivariate analyses were performed to assess the predictive value of having any 
proteinuria and the degree of proteinuria (none, trace, greater-than-trace) after adjusting 
for known and suspected cardiovascular risk factors including age, gender, history of 
diabetes, history of hypertension, history of congestive heart failure, body mass index, 
previous infarction, left ventricular ejection fraction, systolic and diastolic blood 
pressure, baseline GFR, use of diuretics, and treatment assignment.  Participants with 
GFR<60 ml/min/1.73m2 body surface area were considered to have overtly impaired 
kidney function as per recent guidelines (42).  Increased rates of adverse renal and 
cardiovascular events are generally seen below this threshold value, which has been 
utilized in many clinical trials to classify patients with renal dysfunction.  Whether the 
combination of having reduced GFR and proteinuria has an additive impact on outcomes 
 
 was also tested.  We finally evaluated whether proteinuria modified the effect of captopril 
on death or the composite endpoint by assessing the interaction between proteinuria and 
treatment with ACE inhibition. 
 
Worsening Renal Function 
WRF was defined as an increase in creatinine greater-than 0.3mg/dl from 
baseline, which was the threshold value based on receiver operator curve analyses from 
heart failure studies that demonstrated a clinically significant change in creatinine, and 
was less likely to be due to laboratory assay variability (43).  We performed multivariable 
analyses using logistic and Cox regression to assess for independent predictors of WRF.  
The prognostic value of WRF was determined after adjusting for the same covariates as 
in the analysis of proteinuric subjects with the exception of body mass index, and systolic 
and diastolic blood pressure.  We also examined the risk according to treatment 
assignment to see whether captopril is associated with WRF or modifies the relationship 
between WRF and cardiovascular risk.   
In both analyses, Student’s T-test and chi-square tests were used to compare 
continuous and categorical variables between groups.  Cox Proportional Hazards models 
were used to derive univariate and multivariate estimates of risk for outcomes starting 
from baseline in the proteinuria cohort and from the two-week visit after randomization 
when the second creatinine was measured in the WRF cohort.  All-cause mortality and 
cardiovascular mortality were considered primary endpoints.  Stroke, recurrent MI, 
hospitalization for congestive heart failure, and a combination outcome of mortality and 
cardiovascular morbidity were also assessed during a follow-up period of approximately 
 
 42 months in both analyses.  Deaths and cardiovascular endpoints were reviewed by the 
outcomes committee without knowledge of the individual’s treatment assignment or 
laboratory values.  Statistical analyses were performed with STATA software, version 8.2 
(Stata Corp.)   
 
RESULTS 
 
Proteinuria 
 
The baseline characteristics and outcomes of Canadian and U.S. subjects in 
SAVE were generally similar except for a lower incidence of diabetes, hypertension, and 
use of coronary revascularization procedures in Canada (44).  Of the 583 patients with 
baseline creatinine and urine dipstick measures, 122 (20.9%) had proteinuria (trace, n=87 
(14.9%); greater-than-trace, n=35, (6.0%)).  The prevalence of diabetes did not 
significantly differ in patients with or without proteinuria (p=0.18).  Subjects with 
proteinuria were older, more often hypertensive (p=0.03), had a higher baseline serum 
creatinine (p<.001) and Killip class (p<.001), a lower left ventricular ejection fraction 
(p<.001), and were more likely to be taking diuretics (p=0.05) compared to those without 
proteinuria (Table 1).  The mean GFR was lower in subjects with proteinuria (60.9 vs. 
69.9 ml/min/1.73m2, p<0.001), and there was an increasing prevalence of proteinuria 
with decreasing GFR (Figure 1).  Nevertheless, proteinuria was still present in 17.2% of 
patients with a GFR ≥ 60 ml/min/1.73m2. 
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Figure 1. Prevalence of Proteinuria by GFR (ml/min/1.73m2) (n=583) 
 
Proteinuria was associated with a higher risk of death, and was an independent 
predictor of all-cause (hazard ratio [HR] 1.84, 95%CI 1.20-2.82) and cardiovascular 
mortality (HR 1.87, 95%CI 1.18-2.98), after adjusting for known covariates, including 
baseline GFR (Figure 2, Table 2). 
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Figure 2. Death according to the Presence of Proteinuria 
 
The combination of a GFR<60 ml/min/1.73m2 and proteinuria conferred nearly a 
three-fold increased risk of death (HR 2.74, 95%CI 1.68-4.45) compared to having 
neither risk factor (Figure 3).  There was also a stepwise progression of increased risk for 
cardiovascular events according to the degree of proteinuria; patients with a urine 
dipstick result greater-than-trace had a higher incidence of mortality (20.0%, 25.3%, and 
45.7% for no proteinuria, trace, and greater-than-trace, respectively, p for trend=0.002) 
(Figure 4, Table 3).  We found a dose effect for both proteinuria and renal dysfunction, 
with risk increasing in association with heavier proteinuria and lower estimated GFR.  
There was a higher rate of cardiovascular morbidities including stroke, recurrent MI, and 
hospitalization for congestive heart failure in subjects with baseline proteinuria. 
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Figure 3. Death according to Proteinuria (P) and GFR 
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Figure 4. Relative Risk for Endpoints by Degree of Proteinuria  
(Referent group is no proteinuria; n=461) 
  
 
 Subjects with proteinuria appeared to have the greatest reduction in all-cause and 
cardiovascular mortality due to ACE inhibitor therapy.  Assignment to captopril provided 
a greater benefit in lowering risk of death in patients with proteinuria (HR 0.46, 95%CI 
0.24-0.89) versus patients without proteinuria (HR 0.83, 95%CI 0.55-1.25).  The 
composite endpoint also showed an increase in benefit with captopril for subjects with 
proteinuria (0.41, 95%CI 0.21-0.73) compared to those without (0.87, 95%CI 0.63-1.19) 
(Table 4, Figure 5).  In addition, there was a significant test for interaction (p=0.02) for 
the composite endpoint, suggesting that the presence of proteinuria may modify the 
efficacy of captopril and define a subset of patients who obtain additional benefit from 
receiving captopril.   
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Figure 5. Composite endpoint according to Proteinuria (P) and Treatment  
 
 
 
 
 
 Worsening Renal Function 
Subjects who were excluded from this analysis because they were missing serum 
creatinine measurements (n=356), had cardiovascular events (n=21), or were not taking 
medication at two weeks (n=41) were older, more likely to be female, had more 
hypertension, and were more frequent users of diuretics compared with those included in 
the analysis.  Although there was a higher cardiovascular event rate in excluded subjects, 
there was no significant difference in baseline creatinine, change in creatinine, or 
treatment assignment compared with the study cohort. 
The change in creatinine from baseline to two weeks for the 1854 subjects who 
comprised the study cohort was normally distributed, ranging from -1.2 to 2.8 mg/dl with 
a mean change in creatinine by treatment assignment of 0.05 ± 0.3 in both the placebo 
and captopril groups (p=0.9).  There were 223 subjects (12.0%) who had WRF with no 
significant difference in timing of enrollment into SAVE between subjects with and 
without WRF (average 11 days post-MI).  Subjects with WRF were older, more likely 
female, and had a higher prevalence of diabetes, smoking, and use of diuretics, but had 
fewer previous myocardial infarctions (Table 5).  In the multivariate logistic regression 
model, age (odds ratio[OR] 1.02, 95%CI 1.01-1.04) and a history of diabetes (OR 1.45, 
95%CI 1.02-2.05) remained significant predictors of WRF, while use of diuretics (OR 
0.71, 95%CI 0.51-0.97) appeared to protect against WRF in this population of post-MI 
subjects with systolic dysfunction.  
Worsening renal function as early as two weeks after acute MI was associated 
with a higher incidence of death, and was an independent predictor of death (HR 1.55, 
95%CI 1.15-2.11), cardiovascular death (HR 1.71, 95%CI 1.24-2.37), and the composite 
 
 endpoint (HR 1.36, 95%CI 1.07-1.72).  The prognostic value of WRF not only remained 
significant after adjusting for covariates, but was a stronger predictor of cardiovascular 
outcomes than baseline creatinine (HR 1.47, 95%CI 1.05-2.05; HR 1.55, 95%CI 1.07-
2.24; HR 1.38, 95%CI 1.01-1.88 for death, cardiovascular death, and composite endpoint, 
respectively).  There were 104 subjects (5.7%) in the placebo group and 116 subjects 
(6.4%) in the captopril group who had WRF with no difference in the rates of WRF 
between treatment groups (p=0.38).  When stratified by treatment, the risk of death in 
WRF subjects was higher in the placebo group (HR 1.78, 95%CI 1.18-2.68) than in 
patients who were taking captopril at two weeks (HR 1.35, 95%CI 0.85-2.16), as was the 
risk for cardiovascular death and the composite endpoints.  Tests for interaction, 
however, were not significant (p for interaction=0.40, 0.64, and 0.37 for death, 
cardiovascular death, and composite endpoint, respectively) (Figures 6 and 7, Table 6).  
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Figure 6: Event Rate according to WRF and Treatment Assignment 
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Figure 7. Death according to Worsening Renal Function and Treatment 
 
 
DISCUSSION 
 
The pathophysiology behind the cardiorenal syndrome appears to involve a 
complex interaction of positive feedback loops involving the renin-angiotensin system, 
the sympathetic nervous system, oxidative stress, and inflammation.  The combination of 
myocardial injury and renal hypoperfusion leads to a vicious cycle involving these 
feedback loops resulting in further organ damage.  Consequences of the cardiorenal 
syndrome include accelerated atherosclerosis, left ventricular hypertrophy, myocardial 
micro-angiopathy, and decreased capillary density (3).  Because renal dysfunction is a 
common complication of heart failure, the cardiorenal syndrome has been primarily 
studied in this population.  In patients after myocardial infarction, whether the cardiorenal 
syndrome has the same underlying pathophysiology is not as well characterized.  
 
 Furthermore, the management strategy of patients presenting with renal dysfunction in 
the setting of cardiovascular disease is even less defined.    
This thesis aimed to investigate markers of renal dysfunction and the effect of 
early pharmacological intervention with ACE inhibition on cardiovascular outcomes.  
Proteinuria, as measured by standard urine dipstick, and worsening renal function, 
defined as a rise in creatinine greater-than 0.3mg/dl after two weeks, are two distinct 
markers of renal dysfunction.  We observed that in patients with acute MI and systolic 
dysfunction, proteinuria and WRF were common and associated with an increased risk 
for all-cause and cardiovascular mortality after adjustment for known confounders.  
Proteinuria and WRF were independently associated with poorer outcomes even after 
adjustment for baseline creatinine, treatment assignment, and other known covariates.  
The benefit of captopril on cardiovascular mortality was found to be significantly greater 
in patients with proteinuria, but not in patients with WRF. 
 
Proteinuria 
Pathophysiology behind Proteinuria as a Cardiovascular Risk Factor 
The relation between proteinuria and progression to renal failure has been 
extensively studied, and is considered an important predictor of impaired renal function 
(47-49).  One Japanese screening trial of the general population demonstrated that a 
positive urine dipstick had a strong predictive value for developing end-stage renal 
disesase (OR 2.71, 95%CI 2.51-2.92) (50).  Proteinuria has also been described as a risk 
factor for mortality in subjects with chronic diseases and high cardiovascular risk, 
particularly diabetic and hypertensive populations.  Low-grade proteinuria indicates a 
 
 state of increased glomerular permeability that may not be due to glomerular disease 
specifically, but rather to a systemic increase in transcapillary escape of albumin.  
Numerous factors that affect glomerular permeability by acting on podocyte tight 
junctions and arterial permeability by affecting endothelial tight junctions may explain 
the power of albuminuria as a marker and predictor for the presence of vascular disease 
(45).  Proteinuria reflects systemic vascular permeability and endothelial dysfunction that 
may have potential for lipoprotein infiltration into arterial walls and lead to symptomatic 
atherosclerosis (46). 
Albuminuria comprises of microalbuminuria and macroalbuminuria, which are 
defined as urinary albumin excretions between 30-300 and >300 mg/24 hours, 
respectively.  Albumin:creatinine ratios (2.5-25 mg/mmol or >25mg/mmol), which are 
more conveniently measured using spot urine specimens, are also used to quantify 
albuminuria (51).  Microalbuminuria has traditionally been used as a screening measure 
for diabetic nephropathy with an estimated incidence of about 30% in diabetic patients 
and 10-15% in nondiabetics (52).  Recent data have confirmed microalbuminuria as a 
legitimate risk factor for cardiovascular outcomes and a strong predictor of mortality.  
The Heart Outcomes Prevention Evaluation found that the presence of microalbuminuria 
(defined as an albumin/creatinine ratio ≥ 2mg/mmol) predicted adverse outcomes in both 
diabetics (RR 1.97, 95%CI 1.68-2.31) and nondiabetics (RR 1.61, 95%CI 1.36-1.90) (3). 
Clinical proteinuria appears to have prognostic value even in the general 
population.  The Framingham Heart Study evaluated a cohort of older subjects by 
standard urine dipstick, and discovered that baseline trace proteinuria augmented risk of 
death for both men (HR 1.3, 95%CI 1.0-1.7) and women (HR 1.4, 95%CI 1.1-1.7).   
 
 There was an increment in risk of all-cause mortality associated with greater-than-trace 
(HR 1.4, 95%CI 1.1-1.8) compared to trace (HR 1.3, 95%CI 1.1-1.6) proteinuria for the 
Framingham cohort as a whole (p for trend = 0.001) (12).  This analysis from SAVE 
displayed a similar stepwise increase in risk according to the degree of proteinuria.  The 
strength of association between proteinuria and mortality, as detected by a less sensitive 
test such as dipstick urinalysis, reinforces the importance of proteinuria as a risk factor 
for cardiovascular disease. 
The prognostic significance of proteinuria in patients after an acute myocardial 
infarction is less understood.  In 1991, Gosling et al. first noted in 44 patients an increase 
in the albumin excretion rate during MI with a direct correlation between the initial 
urinary albumin:creatinine ratio and size of the infarct (53).  Studies by Berton et al. have 
confirmed this finding, and have shown albuminuria measured during the first week of 
hospitalization post-MI to be predictive of in-hospital, one-year, and three-year mortality 
(54-56).  The albumin:creatinine ratio demonstrated a transient rise and fall during the 
first week post-MI in these studies, and was associated with neurohormonal markers of 
heart failure, including increased renin and aldosterone.  One possible explanation may 
be due to hypoperfusion and prerenal failure producing transient proteinuria in some 
patients (57).  Alternatively, proteinuria, and more specifically albuminuria, may serve as 
an additional marker of early inflammation accompanying infarction or due to coronary 
artery disease.  An association between inflammation and albuminuria has been seen in 
the presence or absence of diabetes or hypertension; recent data has demonstrated 
increased C-reactive protein and white blood cell counts in patients with albuminuria, 
suggesting that inflammatory mediators may play a role in glomerular and renal damage 
 
 (58, 59).  The association between albumin excretion and markers of heart failure and 
inflammation indicates that proteinuria is a comprehensive marker of the 
pathophysiological changes that occur after myocardial infarction (56). 
 
Relationship between Proteinuria and Glomerular Filtration Rate 
The relation between reduced GFR and proteinuria is complex.  There is a lack of 
information on how proteinuria and kidney function may be used together for risk 
stratification.  None of the major clinical trials that have proven the prognostic value of 
either reduced GFR or proteinuria on cardiovascular outcomes tested for potential 
confounding between the two risk factors themselves.  Proteinuria, or more specifically 
albuminuria, and reduced GFR are individual predictors of cardiovascular outcomes, but 
only a handful of studies have explored whether these risk factors act independently from 
each other. Whether a combination of both risk factors exacerbates or simply reflects the 
same amount of kidney disease warrants further study. 
The cross-sectional Third National Health and Nutrition Examination Survey 
(NHANES III) examined 14,622 subjects from the general population (age 20 or over) 
and determined the epidemiology of reduced GFR and albuminuria (60).  Abnormalities 
in renal function were found in 11% of the study population, which would correspond to 
approximately 19.2 million U.S. adults.  The prevalence for reduced GFR (<60 
ml/min/1.73m2) and albuminuria were 6.3% and 9.3%, respectively.  In each risk stratum, 
which included all participants, diabetics, non-diabetic hypertensive participants, and 
non-diabetic non-hypertensive participants, the prevalence of albuminuria increased in a 
step-wise fashion with a declining GFR.  A GFR >60, 30-60, and <30 ml/min/1.73m2 
 
 corresponded to a presence of albuminuria in 8.1%, 23.3%, and 63.4% of the whole 
population, respectively.  Having both albuminuria and reduced GFR was more common 
in older, diabetic, and hypertensive patients.  However, persistent albuminuria with 
preserved GFR may be present in as many as 11.2 million people, suggesting that the 
correlation between renal dysfunction and albuminuria is complex and dependent on the 
population being studied.  The number of persons needed to screen to identify one with 
both reduced GFR and albuminuria was 59 (95%CI 49-74) in the whole population 
compared to 11 (95%CI 9-14) and 28 (95%CI 23-35) in the diabetic and non-diabetic 
hypertensive populations, respectively. 
The African American Study on Kidney Disease and Hypertension trial found an 
inverse relationship between baseline GFR and proteinuria (61).  This relationship was 
evident in our cohort as well, but a substantial proportion (17.2%) of patients in our 
analysis who had a GFR above 60 ml/min/1.73 m2 still had evidence of proteinuria.  The 
HOPE trial demonstrated an additive relationship between microalbuminuria and renal 
dysfunction; patients with both risk factors had a 28.6% incidence of primary outcome 
(cardiovascular death, MI, stroke) versus 13.6% for patients with neither (HR 2.08 
95%CI 1.65-2.62) (52).  However, the HOPE analysis excluded participants with 
proteinuria on dipstick urinalysis, and did not report findings for all-cause mortality.  In 
this analysis from SAVE, we confirmed that proteinuria was associated with death 
irrespective of GFR, and that the combination of both proteinuria and reduced GFR 
additively increased the risk of death by nearly three-fold.   
NHANES III and other studies have demonstrated an increasing prevalence of 
albuminuria with decreasing GFR, particularly when below 60 ml/min/1.73 m2; however, 
 
 albuminuria is also seen in patients who present with renal hyperfiltration.  In early 
diabetic nephropathy, GFR typically follows a biphasic pattern with albuminuria and 
hyperfiltration in the initial phase followed by progression to proteinuria and loss of renal 
function as nephropathy develops (62).  Similar results have been found in nondiabetic 
renal disease.  A large cross-sectional analysis of the PREVEND study (n=7728) found 
an elevated creatinine clearance in subjects with high-normal levels of urinary albumin 
excretion (15-30mg/24hr) and microalbuminuria compared to patients with lower 
excretion (<15mg/24hr).  GFR followed a parabolic pattern in association with increasing 
urinary albumin excretion which then decreased once macroalbuminuria and overt 
proteinuria developed.  High-normal and microalbuminuria were independently 
associated with an elevated filtration rate (RR 1.8, 95%CI 1.3-2.5 and 1.7, 95%CI 1.2-
2.4), and macroalbuminuria with a diminished filtration (RR 4.3, 95%CI 1.9-9.4).  This 
relation persisted even after adjustment for potential confounders.  Limitations of the 
PREVEND analysis, however, may have included selection bias with enrichment for 
albuminuria and more subjects with prediabetes or insulin resistance syndrome (63).  
Having both reduced GFR and albuminuria appears to have an independent but additive 
effect on cardiovascular risk.    
 Whether proteinuria and reduced GFR influence cardiovascular outcomes by the 
same or separate pathophysiological mechanisms requires further study.  Several theories 
have been proposed, but to date no consensus has been reached due to lack of sufficient 
power in clinical trials.  Elevated serum creatinine points to a reduced rate of glomerular 
filtration, while an increased rate of albumin or protein excretion points to a derangement 
in the glomerular filtration barrier.  Proteinuria generally indicates the existence of 
 
 established renal parenchymatous damage.  Animal experiments suggest that increased 
intraglomerular pressure due to hyperfiltration induces proteinuria and progressive renal 
decline.  Insulin resistance has also been reported to regulate GFR and alter permeability 
of the glomerular membrane for albumin (64).  Data from clinical trials support the idea 
that reduced GFR is a distinct entity, whose pathogenesis may be different than 
albuminuria, which typically results from diabetic glomerulosclerosis (65).  Whether one 
direct mechanism of association exists, or if the effects of proteinuria and reduced GFR 
are part of a larger cardiovascular risk profile, is still unclear. 
 
Influence of Proteinuria and Reduced GFR-Analysis from CARE 
In order to better characterize the relative contributions of the combination of 
proteinuria and reduced GFR on cardiovascular risk, we conducted an analysis using data 
from the Cholesterol and Recurrent Events study (CARE) (66).  CARE was a randomized 
trial of pravastatin versus placebo in 4159 individuals with hyperlipidemia and a history 
of myocardial infarction, and has been described in detail elsewhere (67).   Briefly, 
CARE demonstrated that the reduction in LDL concentrations achieved during treatment 
with pravastatin was associated with a reduction in coronary events (68).  We used data 
from 4098 CARE participants who had serum creatinine and proteinuria measured at 
baseline.  Reduced GFR was defined by a GFR<60 ml/min/1.73m2 and proteinuria by 1+ 
or greater protein on dipstick urinalysis.  We examined four mutually exclusive strata 
defined by the presence and absence of reduced GFR and proteinuria.  Cox proportional 
hazards models were used to examine the risk of death and cardiovascular events over 
approximately 60 months of follow-up.    
 
 The findings in CARE were similar to those seen in SAVE.  Subjects who had 
both reduced GFR and proteinuria were at the highest risk of death (HR 2.39, 95%CI 
1.72-3.30) compared to participants with neither proteinuria nor impaired kidney 
function.  There was an intermediate risk for death in subjects with only proteinuria (HR 
1.69, 95%CI 1.32-2.16) or reduced GFR (HR 1.41, 95%CI 1.12-1.79).  There was also 
evidence of a graded increase in the risk of death for both severity of renal impairment 
(estimated GFR ≥60, 45-59.9, and <45 ml/min/1.73m2) and degree of proteinuria by 
dipstick (none, trace, 1+ or greater).  Other cardiovascular outcomes, including new heart 
failure, stroke, and the composite of coronary death or non-fatal myocardial infarction, 
exhibited similar increases in risk.  Limitations included unknown etiologies of renal 
dysfunction in study participants, single baseline dipstick urinalysis and serum creatinine 
measurements, and potential misclassification of subjects with respect to reduced GFR.    
These analyses from both SAVE and CARE demonstrate that in patients with 
either acute or prior myocardial infarction, the risk of death associated with reduced GFR 
is higher with concomitant proteinuria than without.  These results have important 
clinical implications in the management of post-MI patients who have renal dysfunction.  
Using a simple measure such as urine dipstick to assess for proteinuria may help to refine 
estimates of cardiovascular risk which would otherwise be based on kidney function 
alone.  
 
 
 
 
 
 Impact of ACE Inhibition on Proteinuria and Cardiovascular Outcomes 
Interventions known to delay or prevent progression of renal disease and reduce 
cardiovascular risk include tight control of blood pressure and glucose, and inhibition of 
the renin-angiotensin system.  Lipid-lowering therapy has also been associated with 
protective effects.  Previous analyses from CARE have shown that treatment with 
pravastatin significantly reduced rates of renal decline in individuals with moderate renal 
insufficiency.  The beneficial effects of pravastatin on preventing loss of renal function 
were greater in patients not only with lower levels of GFR at baseline, but also in subjects 
with proteinuria (69).  In the Pravastatin Pooling Project, the absolute benefit in reduction 
of adverse outcomes from using pravastatin was greater in patients with chronic kidney 
disease (70).  Results from CARE and additional studies have justified the use of statin 
therapy in patients with chronic kidney disease to slow progression of renal failure and to 
prevent cardiovascular events. 
ACE inhibitors and angiotensin-receptor blockers have been proven to be 
nephroprotective in patients with reduced GFR and proteinuria, but whether improved 
renal function leads to a reduction in cardiovascular risk independent of blood pressure 
effects has not been specifically addressed.  We observed in SAVE that treatment with 
captopril showed the greatest absolute benefit in reducing cardiovascular events in post-
MI subjects with trace or higher proteinuria.  Kaplan-Meier survival curves (Figure 5) 
demonstrated a dramatic attenuation of risk (59%, p<.002) for subjects with proteinuria 
taking captopril compared to placebo and a significant interaction between captopril and 
proteinuria (p=0.02).  In contrast, the risk reduction of captopril in patients without 
proteinuria was not significant (13%, p=0.37). 
 
 The explanation for this novel finding remains unclear.  Clinical benefits in 
patients with albuminuria taking ACE inhibitors or angiotensin-receptor blockers, which 
can lower urinary albumin excretion by an average of 40% irrespective of its effect on 
blood pressure, have been reported (46).  A meta-analysis of antihypertensive 
medications indicated that the mean antiproteinuric effect of ACE inhibitors was greater 
than of other antihypertensive drugs despite similar blood pressure lowering between 
both groups (71).  Studies have suggested that the benefits of ACE inhibitors in reducing 
progression of renal disease are greater for patients with proteinuria at onset of treatment 
or during follow-up (49).  The HOPE trial examined the use of ACE inhibition in 
improving GFR and microalbuminuria and its potential influence on cardiovascular 
outcomes.  Low-dose ramipril reduced incidence of outcomes in patients with and 
without renal dysfunction and albuminuria.  The cardiovascular benefits of ramipril were 
greater in patients with both risk factors (HR 0.48 95%CI 0.24-0.98) compared to those 
with neither (HR 0.78 95%CI 0.70-0.87) (62).  A recent study by Asselbergs et al. 
randomized 864 subjects with microalbuminuria to fosinopril or placebo, and found that 
treatment with fosinopril lowered urinary albumin excretion by 26% (p<.001).  Although 
not significant, the incidence of cardiovascular morbidity or mortality was also lowered 
by 40% (HR .60, 95%CI 0.33 to 1.10) (72). 
The added benefit seen in proteinuric patients most likely reflects the increased 
risk observed in this population.  Although this finding is hypothesis-generating and must 
be validated with larger clinical trials designed to examine the cardiovascular benefits in 
proteinuric patients, it appears that proteinuria may define a subgroup of post-MI patients 
who are more sensitive to the protective effects of captopril. 
 
 Worsening Renal Function 
Changes in Creatinine and Cardiovascular Risk 
Although baseline renal dysfunction is considered a potent cardiovascular risk 
factor in post-MI patients, the predictive value of worsening renal function has not yet 
been adequately addressed in this population.  The majority of studies that have examined 
the prognostic value of reduced renal function have focused on serum creatinine values or 
GFR at one point in time.  The predictive value of an increase in creatinine over time, 
however, has been less clear, and has primarily been determined in patients hospitalized 
for heart failure, in which the incidence of WRF (27% and 28%) was consistently greater 
than that seen in this analysis (12.0%) (23, 24).  More risk factors have proven predictive 
of WRF in the heart failure population (baseline creatinine, systolic blood pressure, 
history of diabetes or congestive heart failure) than were seen in this population of post-
MI subjects with systolic dysfunction (age, history of diabetes).   
Few trials have assessed the prognostic value of WRF in the setting of coronary 
artery disease.  Shilpak et al. examined the influence of a change in creatinine greater-
than 0.3mg/dl, in postmenopausal women with coronary artery disease in the Heart and 
Estrogen/Progestin Replacement Study (73), and observed no association between 
subjects with WRF (9% of cohort) and cardiovascular risk.  In this healthier population 
with stable coronary disease, changes in creatinine were measured longitudinally over 
four years, however, and thus may have been relatively small.   
Most clinical studies have defined WRF as an increase in creatinine greater-than 
0.3mg/dl, a threshold that has been found in prior studies to have the highest sensitivity 
(81%) and specificity (62%) for predicting mortality (43).  Initial analyses in our cohort 
 
 demonstrated a similar threshold effect with a higher event rate occurring in subjects with 
a change in creatinine greater-than 0.3 mg/dl.  Lower magnitude changes may be less 
clinically relevant and represent transient changes or inherent variability in creatinine 
measurement.  However, a more linear or J-shaped association between small changes in 
creatinine and risk for adverse cardiovascular outcomes has also been suggested (74, 75).  
An acute rise in creatinine of at least 25-30% has also been recommended as a threshold 
for WRF (76).  Although the various thresholds may vary according to patient 
population, there is definitive evidence that small changes in creatinine confer adverse 
prognostic value. 
 
ACE Inhibition and Reduced Renal Function-Analysis from PEACE 
 Physicians are hesitant to use ACE inhibitor therapy in patients with renal 
dysfunction.  This remains the norm in clinical practice despite recent data that has 
demonstrated the efficacy and safety of ACE inhibition in patients without diabetes who 
have advanced renal insufficiency, irrespective of baseline GFR or blood pressure (77).  
Results from the clinical trial by Hou et al. indicated that end-stage renal disease would 
take almost twice as long to develop in the patients given benazepril (7 years) compared 
to the control cohort (3.5 years).  While this evidence suggests the safety of ACE 
inhibition in nondiabetic patients with renal insufficiency, the use of ACE inhibitors in 
patients with coronary artery disease and renal dysfunction requires further investigation. 
We explored the influence of renal function, using estimated GFR, on 
cardiovascular outcomes and the response to ACE inhibition in the recently published 
Prevention of Events with ACE Inhibition (PEACE) trial (78).  PEACE did not 
 
 demonstrate a benefit of the ACE inhibitor trandolapril in reducing cardiovascular 
morbidity or mortality in patients with stable coronary disease and preserved left 
ventricular systolic function (79).  Unlike the results that were observed in the HOPE and 
EUROPA trials demonstrating the cardiovascular benefit of ACE inhibition in patients 
with chronic coronary artery disease, the lack of benefit observed in PEACE was 
attributed to an overall lower risk patient population.  The majority of patients enrolled in 
PEACE had received effective concomitant therapy, such as coronary revascularization 
and statins more frequently than patients in the previous trials. 
The PEACE trial included patients at least 50 years old, with stable coronary 
artery disease and preserved systolic function who were randomly assigned to treatment 
with the ACE inhibitor trandolapril or to placebo and followed for a median of 4.8 years 
(80).  A total of 8290 patients were enrolled in PEACE.  Of these, 10 patients had 
missing data on baseline serum creatinine and/or race, variables required to estimate 
glomerular filtration rate, and were therefore excluded, leaving 8280 patients for this 
analysis.  Cox proportional hazards models were used to conduct a post-hoc analysis 
examining the association between GFR and cardiovascular endpoints.  Potential 
confounding variables that were considered in the models included age, sex, history of 
diabetes, history of myocardial infarction, hypertension, and left ventricular ejection 
fraction (<0.50; ≥0.50).  We also examined GFR as a categorical variable to aid in the 
interpretation of potential interaction between GFR (<60.0; ≥60.0 ml/min/1.73m²) and 
treatment group. 
The mean GFR was 77.6 ± 19.4 ml/min/1.73m²; 1355 (16.3%) patients had 
reduced renal function (GFR<60 ml/min/1.73m²).  In patients with reduced renal 
 
 function, trandolapril was associated with a reduction in total mortality (HR 0.73, 95%CI 
0.54-1.00).  This benefit was not demonstrated in patients with preserved renal function 
(HR 0.94, 95%CI 0.78-1.13).  We observed a significant interaction between GFR and 
treatment group with respect to cardiovascular and all-cause mortality (p = 0.02), 
suggesting that ACE inhibition modifies the relationship between GFR and outcome.  
Not only did trandolapril attenuate the relationship between decreasing GFR and 
mortality, but the effectiveness of trandolapril appeared to increase as GFR decreased.   
A previous SAVE analysis demonstrated a trend similar to that found in PEACE 
where patients with reduced GFR taking captopril had a nominally greater reduction in 
cardiovascular risk than those taking placebo (19).  However, there was not a statistically 
significant interaction between reduced GFR and captopril (p=0.29) as was seen in 
PEACE.  In contrast to the findings in SAVE, in which ACE inhibitors were as effective 
in patients with reduced GFR as in those with preserved renal function, this analysis from 
PEACE suggests that ACE inhibitors were only effective for reducing all-cause and 
cardiovascular mortality in patients with reduced renal function.  These results may be 
related to the relatively low-risk patient population, and could help explain the lack of 
overall benefit in PEACE.  While hypothesis generating, these data indicate that ACE 
inhibition may be most effective at lowering cardiovascular risk in patients with reduced 
GFR.  Patients with stable coronary artery disease and reduced GFR may more likely 
benefit from the cardiovascular protective effects of ACE inhibition.  
 
 
 
 
 Clinical Implications of ACE Inhibition in Patients with WRF 
The decision to withdraw ACE inhibition in patients who experience small 
elevations in serum creatinine has been controversial (81).  Physicians are reluctant to 
continue treatment with ACE inhibitors when creatinine begins to rise for concerns of 
precipitating acute renal failure (76).  However, minor increases in serum creatinine that 
occur with initiation of ACE inhibitor may paradoxically indicate improved renal 
hemodynamics, at least in the setting of proteinuric renal disease, and have been 
associated with long-term preservation of renal function (36, 37, 82).  More rapid 
increases would suggest conditions such as bilateral renal artery stenosis or severe 
hypoperfusion, and would warrant discontinuation of ACE inhibition.  Butler et al. did 
not find an association between WRF and ACE inhibitors in heart failure patients (83).  
Similarly, we did not observe a greater incidence of WRF in patients receiving ACE 
inhibition in SAVE. 
Our data may suggest that the relationship between WRF and increased 
cardiovascular risk could be altered by ACE inhibitor therapy in patients after myocardial 
infarction.  While a formal test for interaction was not significant, most likely due to 
inadequate sample size and statistical power given the relatively small number of subjects 
with WRF for each endpoint, the increased risk associated with WRF still appeared to be 
attenuated in the captopril group.  We thus cannot exclude the possibility that ACE 
inhibition may alter the relationship between elevation in creatinine and cardiovascular 
outcomes given the consistently lower risk for each primary endpoint.  Recommendations 
for starting ACE inhibitor therapy in patients with renal dysfunction include beginning 
with a conservative initial dose, increasing the dose only when well-tolerated, and having 
 
 once-daily morning dosing to permit nocturnal excretion of potassium to avoid 
hyperkalemia (84).  Although there is no convincing evidence based on pharmakinetics 
that one ACE inhibitor is superior to another in providing renal and cardiovascular 
benefits, captopril would not be recommended over ACE inhibitors that are once-daily 
dosing because its shorter half-life would likely increase noncompliance and 
undertreatment.  Blood pressure, renal function, and serum potassium levels should be 
closely monitored in patients with renal dysfunction and changes in serum creatinine, 
particularly during the first few months after initiation of ACE inhibitor therapy.   
 
Limitations 
 This assessment of the impact of renal dysfunction and response of ACE 
inhibition in post-MI patients with left ventricular dysfunction is not without limitations.  
In the case of proteinuria, because only a subset of patients enrolled in SAVE underwent 
dipstick analysis, our statistical power is limited.  Nevertheless, even in this small 
sample, we are able to demonstrate an independent increase in cardiovascular risk 
associated with proteinuria and a clear differential benefit to ACE inhibitor therapy in 
this population.  Dipstick urinalysis gives only a crude estimate of protein excretion, 
which may vary depending on the hydration status of the patient.  Tests with a higher 
sensitivity and specificity for quantifying microalbuminuria may be more accurate 
indicators of cardiovascular risk (85).  However, the ability of a qualitative measure such 
as dipstick urinalysis to demonstrate significant risk according to the degree of 
proteinuria emphasizes the importance of proteinuria as a cardiovascular risk factor.  
Sodium intake, which was not quantified, is known to blunt the antiproteinuric effects of 
 
 ACE inhibitors in spite of blood pressure reduction, and may have influenced the 
response to treatment with captopril (86, 87).   
In the analysis of WRF, serum creatinine was measured two weeks after 
randomization, which occurred on average eleven days post-infarction.  The variation in 
time may have affected the results through either deterioration or improvement of renal 
function.  However, this variation in time underscores not only the prognostic value of 
WRF, but also emphasizes the value of measuring serum creatinines anywhere from one 
to three weeks after the acute event and during outpatient follow-up for accurate risk 
stratification.  Subjects who were excluded from the analysis due to missing serum 
creatinine measurements or cardiovascular events prior to two weeks demonstrated a 
higher rate of events during follow-up.  Although this introduces possible selection bias, 
there was no difference in baseline creatinine, change in creatinine, or treatment 
assignment compared with the study cohort and thus should not have altered the 
influence of WRF on cardiovascular risk.   
The dose of study medication (placebo or captopril) was also variable; titration 
regimens were left to the discretion of each subject’s physician.  Subjects who tolerated 
the initial test dose were included regardless if the study medication was not fully titrated 
to the target dose of 25mg TID by the end of two weeks.  The majority of subjects were 
started at 12.5mg and titrated upwards, but there were subjects who started at lower doses 
or were down-titrated due to adverse drug reactions or cardiovascular events prior to two 
weeks, which might influence the predictive value of increased creatinine.  Our findings 
in the placebo group, however, would not have been influenced by dose titration. 
 
   Finally, SAVE was conducted between 1988-1991, and thus we cannot exclude 
the possibility that changes in the management of post-MI patients may have altered the 
current relation between proteinuria, worsening renal function, and cardiovascular risk.  
However, SAVE was conducted in a randomized, placebo-controlled setting, and 
therefore allowed us to assess the true effect of ACE inhibition on cardiovascular 
outcomes in the setting of renal dysfunction. 
 
CONCLUSIONS 
 
In summary, we observed that two markers of renal disease, proteinuria and 
worsening renal function, are associated with significantly increased risk for 
cardiovascular outcomes and mortality in patients with systolic dysfunction after 
myocardial infarction.  This association is independent of baseline renal function, as 
assessed by estimated glomerular filtration rate.  The benefit of captopril in reducing 
cardiovascular morbidity and mortality was greatest in patients with proteinuria, 
suggesting that this measure may help identify a group of patients who are at higher risk.  
Although a significant interaction between worsening renal function and ACE inhibition 
was not demonstrated, the risk was most prominent in patients receiving placebo, and 
appears to be attenuated in patients receiving captopril.  
Given the rising incidence of chronic kidney disease in the United States, 
understanding the cardiovascular risk associated with having one or both of these markers 
of kidney disease is of profound clinical importance.  The cardiorenal syndrome, which 
has primarily been studied in the heart failure population, needs to be better characterized 
 
 in patients after myocardial infarction as it may help in elucidating the complex 
pathophysiology surrounding this growing problem.  These findings suggest the 
importance of using relatively simple and inexpensive measures, such as urine dipstick 
analysis and serum creatinine, to follow renal function during the first few weeks after 
acute myocardial infarction.  Even during outpatient follow-up, close monitoring for 
renal dysfunction may aid in long-term risk stratification for cardiovascular events.  
These results not only appear to identify the additional benefit post-MI patients who have 
proteinuria receive from ACE inhibitor therapy, but may argue against discontinuation of 
ACE inhibitor therapy after small, nonprogressive increases in creatinine.  However, 
more data from clinical trials are needed to better understand the interaction between 
kidney and cardiovascular disease, and to improve utilization of aggressive therapeutic 
strategies, such as ACE inhibition.    
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 TABLES 
Table 1. Comparison of Baseline Characteristics of Patients by Proteinuria  
CharacteristicsA (-) Proteinuria 
(n=461) 
(+) Proteinuria 
(n=122) 
P-value 
Age (yr) 59.7 ±10.5 62.3 ± 9.7 .003  
Baseline Creatinine 
(mg/dl) 
1.16 ± 0.3 1.35 ± 0.5 <.001 
Baseline eGFR 
(ml/min/1.73m2) 
69.9 ± 19.6 60.9 ± 19.2 <.001 
Systolic BP 112.7 ±14.5 115.7 ± 18.7 .08 
Diastolic BP 70.5 ±10.4 70.3 ±11.5 .83 
Body Mass Index 26.4 ± 4.2 26.5 ± 4.5 .75 
Female gender (%) 91 (19.7) 22 (18.0) .67 
LVEF (%) 31.2 ± 6.5 29.8 ± 7.7 .05 
Killip class ≥2 (%) 165 (35.8) 65 (53.3) <.001 
Hypertension (%) 155 (33.6) 54 (44.3) .03 
Diabetes (%) 81 (17.6) 28 (22.9) .18  
Previous MI (%) 163 (36.2) 35 (29.2) .15 
History of CHF (%) 20 (4.3) 5 (4.1) .91 
Ever smoked (%) 102 (22.1) 29 (23.8) .70 
Alcohol use (%) 269 (58.3) 66 (54.1) .40 
MedicationsB:    
Diuretics (%) 169 (39.5) 54 (50.0) .05 
B-blockers (%) 140 (32.1) 35 (31.8) .95 
Captopril 
Assignment (%) 
231 (50.1) 64 (52.5) NSC
A Plus-minus values are mean ± SD; Student’s t-test for continuous variables, chi2 for categorical 
B Medications-sustained drug treatment within 24 hours prior to randomization 
C by design 
 
 Table 2. Outcomes by Proteinuria in Cox Proportional Hazard Models 
Outcomes (-) Proteinuria 
(n=461) 
(+) Proteinuria 
(n=122) 
Univariate 
Analyses 
Multivariate 
AnalysesA
 Events (%) Events (%) HR (95%CI) HR (95%CI) 
Death 92 (20.0) 38 (31.1) 1.63 (1.12-2.38) 1.84 (1.20-2.82) 
Cardiovascular 
Death 
79 (17.1) 33 (27.1) 1.64 (1.09-2.46) 1.87 (1.18-2.98) 
Death or 
Stroke 
100 (21.7) 41 (33.6) 1.65 (1.15-2.38) 1.83 (1.21-2.98) 
Death or MI 
 
123 (26.7) 45 (36.9) 1.47 (1.05-2.07) 1.52 (1.03-2.24) 
Death or CHF 
Hospitalization 
123 (26.7) 43 (35.2) 1.40 (.99-1.99) 1.57 (1.06-2.32) 
CompositeB 
 
152 (33.0) 51 (41.8) 1.35 (0.98-1.86) 1.41 (0.99-2.02) 
A Multivariate model adjusted for age, gender, previous MI, history of hypertension, history of diabetes, 
history of CHF, body mass index, systolic/diastolic blood pressure, left ventricular ejection fraction , 
glomerular filtration rate, use of diuretics, and study medication (captopril vs placebo).   
B Composite Endpoint includes death, recurrent MI, CHF hospitalization, and stroke 
HR = hazard ratio; CI = confidence interval; MI = myocardial infarction; CHF = congestive heart failure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3. Association of  Degree of Proteinuria with OutcomesA 
 
Outcomes Events 
(%) 
Univariate Analysis 
HR (95% CI) 
Multivariate Analysis 
HR (95% CI) 
Death    
Trace (n=87) 22 (25.3) 1.33 (.84-2.12) 1.46 (.89-2.41) 
> Trace (n=35) 16 (45.7) 2.37 (1.39-4.03) 2.30 (1.29-4.09) 
P for trend  .002 .003 
Cardiovascular Death    
Trace (n=87) 19 (21.8) 1.33 (.81-1.20) 1.55 (.90-2.67) 
> Trace (n=35) 14 (40.0) 2.39 (1.35-4.22) 2.30 (1.24-4.26) 
P for trend  .003 .004 
Death or Stroke    
Trace (n=87) 24 (27.6) 1.38 (.88-2.16) 1.51 (.94-2.42) 
> Trace (n=35) 17 (48.6) 2.30 (1.37-3.84) 2.20 (1.26-3.82) 
P for trend  .001 .002 
Death or MI    
Trace (n=87) 28 (32.2) 1.31 (.87-1.98) 1.38 (.89-2.12) 
> Trace (n=35) 17 (48.6) 1.86 (1.12-3.08) 1.66 (.97-2.85) 
P for trend  .011 .03 
Death or CHF 
Hospitalization 
   
Trace (n=87) 27 (31.0) 1.26 (.83-1.92) 1.44 (.92-2.24) 
> Trace (n=35) 16 (45.7) 1.72 (1.02-2.90) 1.46 (.84-2.55) 
P for trend  .03 .067 
Composite Endpoint    
Trace (n=87) 33 (37.9) 1.25 (.86-1.83) 1.34 (.90-1.99) 
> Trace (n=35) 18 (51.4) 1.57 (.96-2.57) 1.33 (.79-2.23) 
P for trend  .042 .122 
A Patients with no proteinuria (n=461) as the referent Group 
 
 
 
 Table 4. Efficacy of Captopril by Proteinuria 
Variable Placebo 
Events/Pts (%) 
Captopril 
Events/Pts (%) 
HRA   
(95% CI) 
Test for 
Interaction 
Death     
(-)Proteinuria 50/230 (21.7) 42/231 (18.2) .83 (.55, 1.25)  
(+)Proteinuria 23/58 (39.7) 15/64 (23.4) .46 (.24, .89) P=.14 
SAVE  275/1116 (24.6) 228/1115 (20.4) .81 (.68, .97)   
Cardiovascular Death    
(-)Proteinuria 48/230 (20.9) 31/231 (13.4) .64 (.40, 1.00)  
(+)Proteinuria 21/58 (36.2) 12/64 (18.7) .40 (.20, .81) P=.29 
SAVE  234/1116 (20.9) 188/1115 (16.9) .79 (.65, .95)  
Composite EndpointB    
(-)Proteinuria 80/230 (34.8) 72/231 (31.2) .87 (.63, 1.19)  
(+)Proteinuria 31/58 (53.4) 20/64 (31.2) .41 (.23, .73 ) P=.02 
SAVE  450/1116 (40.3) 395/1115 (35.4) .84 (.73, .96)  
A Hazard Ratio was calculated using unadjusted Cox proportional hazards model 
B Composite Endpoint includes death, recurrent MI, CHF hospitalization, and stroke 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 5. Baseline Characteristics according to Worsening Renal Function (WRF)  
CharacteristicsA ∆Cr ≤ .3 (n=1631), 
88.0% 
∆Cr > .3 (n=223), 
12.0% 
P-value 
Age (yr) 58.8 ± 10.6  60.7 ± 10.8 .01 
Creatinine (mg/dl) 
 
1.20 ± .32 1.09 ± .35 <.001 
LVEF (%) 31.3 ± 6.6 30.7 ± 6.4 .20 
Systolic BP 112 ± 15 114 ± 16 .06 
Diastolic BP 70 ± 10 70 ± 10 .99 
Female gender (%) 257 (15.7%) 53 (23.8%) .003 
GFR < 60 
ml/min/1.73m2
549 (33.7%) 61 (27.3%) .06 
Hypertension (%) 677 (41.5%) 103 (46.2%) .18 
Diabetes (%) 333 (20.4%) 62 (27.8%) .012 
Previous MI (%) 584 (37.6%) 63 (29.4%) .020 
History of CHF (%) 99 (6.1%) 9 (4.0%) .22 
Smoking (%) 328 (20.1%) 60 (26.9%) .019 
MedicationsB:    
Diuretics (%) 538 (34.5%) 89 (41.9%) .034 
Captopril Therapy 819 (50.2%) 119 (53.4%) .38C  
A Plus-minus values are mean ± SD; Student’s t-test for continuous variables, chi2 for categorical 
B Medications-sustained drug treatment within 24 hours prior to randomization 
C By design 
 
 
 
 
 
 
 
 
 
 Table 6. Events and Risk in Patients according to presence of WRF and Treatment 
Events 
(%) 
∆Cr≤.3 
(n=1631) 
∆Cr>.3 
(n=223)
Unadjusted 
HR  
(95%CI) 
Adjusted 
HRA 
(95%CI) 
Adjusted  HR by 
Treatment (n=1813) 
(95%CI) C
     Placebo 
(n=916) 
Captopril 
(n=897)D
Death 316 
(19.4%) 
58 
(26.0%)
1.46 
(1.10-1.93) 
1.55 
(1.15-2.11) 
1.78 
(1.18-2.68) 
1.35 
(.85-2.16) 
CV Death 260 
(15.9%) 
51 
(22.9%)
1.55 
(1.15-2.09) 
1.71 
(1.24-2.37) 
1.89 
(1.20-2.97) 
1.57 
(.97-2.55) 
Death and 
MI 
438 
(26.8%) 
72 
(32.3%)
1.33  
(1.03-1.70) 
1.28  
(.97-1.68) 
1.45  
(1.00-2.11) 
1.14 
(.75-1.73) 
Death and 
CHF 
443 
(27.2%) 
78 
(34.9%)
1.51  
(1.19-1.93) 
1.48  
(1.13-1.92) 
1.70  
(1.19-2.43) 
1.33  
(.89-1.97) 
Composite 
EndpointB
564 
(34.6%) 
94 
(42.1%)
1.41 
(1.14-1.76) 
1.36 
(1.07-1.72) 
1.57 
(1.13-2.17) 
1.22 
(.86-1.75) 
AAdjusted for age, sex, baseline creatinine, GFR <60ml/min/1.73m2, history of hypertension, history of diabetes, 
history of CHF, left ventricular ejection fraction, previous myocardial infarction, use of diuretics, treatment 
assignment 
BComposite endpoint: Death, MI, CHF Hospitalization, Stroke; 
CFrom the original cohort of 1854 subjects, 41 were excluded who were not taking captopril at two weeks due to 
adverse drug reactions (hypotension, dizziness) in order to stratify risk associated with WRF by treatment 
DTest for interaction: p >.15 
HR: Hazard Ratio; CI: Confidence Interval 
 
 
